Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
Condition: Respiratory Syncytial Virus Infections Interventions: Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A; Biological: Bexsero; Biological: Nimenrix; Biological: Menveo; Biological: Synflorix; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials